Integrated Training in Pharmacological Sciences

药理学科学综合培训

• 批准号: 10642793
• 负责人: Avner Schlessinger
• 金额: $ 27.31万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-05 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10642793
• 关键词: Science; Training; pharmacologic

PROJECT SUMMARY This is a renewal application of a training program at Icahn School of Medicine at Mount Sinai that is currently in its 17th year. In previous project periods, we have developed an innovative program in pharmacological sciences that has helped to establish Mount Sinai as one of the leaders in the nascent field of systems pharmacology. We were early advocates of introducing quantitative and computational training for all PhD candidates in biomedical sciences, and this remains the cornerstone principle of our curriculum. In coursework, students apply quantitative/computational approaches through problem solving and active learning exercises, and fundamental biological concepts underlying drug discovery and drug action are communicated within a disease context that promotes engagement. In addition to the rigorous and innovative curriculum, trainees in our program benefit from activities that enhance the research experience, including journal clubs, Works-in- Progress seminars, an annual retreat focused on career development, and an annual systems pharmacology symposium that provides networking opportunities. The coming project period will build on these successes and introduce new initiatives including flipped classrooms to maximize trainee flexibility, a new course that will be co-taught by pharmaceutical industry scientists, and formal training for all program mentors. For dissertation research, trainees can be mentored by any of 42 well-funded investigators with expertise in approaches in varied areas of pharmacology such as structure-based drug design, mathematical modeling of pathophysiology and drug action, and bioengineering. Students address cutting edge issues that must be solved to develop safe and effective therapeutics in disease areas such as cancer, cardiovascular disease, neurological disorders, diabetes, and kidney and liver disease. This structure has proven highly effective at producing successful young scientists. Trainees who have completed the program during the past 10 years have finished their PhDs in an average of 5.1 years and have typically produced nearly 5 total publications (average 4.88) and over 2 first author publications (average 2.2) resulting from their time in training at Mount Sinai. Program alumni have gone on to successful careers that collectively address many aspects of pharmacological sciences, both in academia and in the pharmaceutical industry. We aim to continue to innovate and develop trainees who will become tomorrow’s leaders in pharmacology and address the urgent need for new approaches in drug development.

项目摘要 这是西奈山伊坎医学院的培训计划的续签应用程序，目前是 在17年。在以前的项目期间，我们开发了一项药理创新计划 有助于建立西奈山的科学，成为系统新生领域的领导者之一 药理。我们是提出所有博士学位的定量和计算培训的早期拥护者 生物医学科学的候选人，这仍然是我们课程的基石原则。在课程中， 学生通过解决问题和主动学习练习应用定量/计算方法， 在药物发现和药物作用的基本生物学概念和药物作用的基本概念都在 促进参与的疾病环境。除了严格和创新的课程外，学员还在 我们的计划受益于增强研究经验的活动，包括期刊俱乐部，工作 进度下水道，年度务虚会，专注于职业发展和年度系统药理学 提供网络机会的研讨会。即将到来的项目时期将以这些成功为基础 并介绍包括翻转教室在内的新举措，以最大程度地提高学员的灵活性，这是一门新课程 由制药行业科学家共同教授，并为所有计划导师进行正规培训。 对于论文研究，可以将学员考虑到具有专业知识的42名资金资助的调查员中的任何一项 药理学领域的方法，例如基于结构的药物设计，数学建模 病理生理学和药物作用以及生物工程。学生解决必须是的最前沿问题 被解决以在癌症，心血管疾病等疾病地区开发安全有效的治疗， 神经系统疾病，糖尿病，肾脏和肝病。这种结构已被证明非常有效 生产成功的年轻科学家。在过去的10年中完成了该计划的学员 平均完成了5。1年的博士学位，并且通常生产近5个出版物 （平均4.88）和超过2位第一作者出版物（平均2.2），这是由于他们在Mount培训的时间 西奈。计划校友继续从事成功的职业，共同解决了许多方面 在学术界和制药行业的药理学科学。我们的目标是继续 创新和发展受训者，他们将成为明天的药理学领导者，并解决紧急情况 需要在药物开发方面采用新方法。

项目成果

Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency.

• DOI: 10.1073/pnas.2210247119
• 发表时间: 2022-11-16
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1

The three-dimensional landscape of cortical chromatin accessibility in Alzheimer's disease.

• DOI: 10.1038/s41593-022-01166-7
• 发表时间: 2022-10
• 期刊: NATURE NEUROSCIENCE
• 影响因子: 25
• 作者: Bendl, Jaroslav;Hauberg, Mads E.;Girdhar, Kiran;Im, Eunju;Vicari, James M.;Rahman, Samir;Fernando, Michael B.;Townsley, Kayla G.;Dong, Pengfei;Misir, Ruth;Kleopoulos, Steven P.;Reach, Sarah M.;Apontes, Pasha;Zeng, Biao;Zhang, Wen;Voloudakis, Georgios;Brennand, Kristen J.;Nixon, Ralph A.;Haroutunian, Vahram;Hoffman, Gabriel E.;Fullard, John F.;Roussos, Panos
• 通讯作者: Roussos, Panos

Molecular Basis of Human Trace Amine-Associated Receptor 1 Activation.

人类痕量胺相关受体 1 激活的分子基础。

• DOI: 10.1101/2023.09.06.556555
• 发表时间: 2023
• 期刊: bioRxiv : the preprint server for biology
• 作者: Zilberg,Gregory;Parpounas,AlexandraK;Warren,AudreyL;Yang,Shifan;Wacker,Daniel
• 通讯作者: Wacker,Daniel

Hydrogel-Embedded Poly(Lactic-co-Glycolic Acid) Microspheres for the Delivery of hMSC-Derived Exosomes to Promote Bioactive Annulus Fibrosus Repair.

• DOI: 10.1177/19476035221113959
• 发表时间: 2022-07
• 期刊: CARTILAGE
• 影响因子: 2.8
• 作者: DiStefano, Tyler J.;Vaso, Keti;Panebianco, Christopher J.;Danias, George;Chionuma, Henry N.;Kunnath, Kuriakose;Karoulias, Stylianos Z.;Wang, Minghui;Xu, Peng;Dave, Rajesh N.;Sahoo, Susmita;Weiser, Jennifer R.;Iatridis, James C.
• 通讯作者: Iatridis, James C.

A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility.

• DOI: 10.1038/s41525-022-00324-x
• 发表时间: 2022-09-05
• 期刊: NPJ genomic medicine
• 影响因子: 5.3
• 作者: Voloudakis G;Vicari JM;Venkatesh S;Hoffman GE;Dobrindt K;Zhang W;Beckmann ND;Higgins CA;Argyriou S;Jiang S;Hoagland D;Gao L;Corvelo A;Cho K;Lee KM;Bian J;Lee JS;Iyengar SK;Luoh SW;Akbarian S;Striker R;Assimes TL;Schadt EE;Lynch JA;Merad M;tenOever BR;Charney AW;Mount Sinai COVID-19 Biobank;VA Million Veteran Program COVID-19 Science Initiative;Brennand KJ;Fullard JF;Roussos P
• 通讯作者: Roussos P